GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
Abigail Agius Mamo warns gender quotas may be needed until 2046 at current pace
She argued that the gender mechanism reinforces the stereotype it claims to fight.
‘Stop making rubbish regulations’: Ryanair CEO slams EU air passenger rights reform
Europe’s Air Traffic Control system accounts for over 90% of airline delays, Ryanair boss says.
What DR Congo’s World Cup fashion statement can teach leaders about standing out
Sometimes success is about recognising where you cannot realistically dominate, then finding a creative way to become impossible to ignore.
Claude Mifsud assumes dual Chief Technology Officer and Chief AI Officer role at Concept Stadium
'We see technology as a natural extension of our advisory role,' Claude Mifsud says.
